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Gastroesophageal cancer (GEC) remains a challenging problem in oncology. Anatomically, GEC is comprised of distal
gastric adenocarcinoma (GC), classically associated with Helicobacter Pylori, while proximal esophagogastric
adenocarcinoma (EGJ AC) has increased significantly in incidence over the past years. Despite contrasting etiologies,
histologies, and molecular phenotypes of distal and proximal GEC, in many cases perioperative (and metastatic)
treatment strategies converge to similar approaches. For patients undergoing curative intent surgery, advances in
perioperative chemotherapy and/or chemoradiotherapy, either before and/or after surgery, have demonstrated
improved survivals compared to surgery alone. This review focuses on how the ‘boundary’ of the Z-line and/or the
anatomical distinction of ‘proximal’ (EGJ) vs. ‘distal’ (GC) cancer has led to diverse inclusion/exclusion criteria for
clinical trial enrollment, embodying various combinations of chemotherapy and radiation before and/or after surgery.
Supporting evidence of each of these approaches consequently has led to a number of varying practices by
geographical region and Institution/Physician, based on differing experience, preference, and clinical circumstance.
Adequate direct comparison of these approaches is lacking currently, but data from a number of concerted efforts
should be available in the next years to further direct best standards of care. Introduction of biologically targeted
agents, namely anti-angiogenics and anti-HER family therapeutics are being evaluated to determine whether further
therapeutic gains can be realized over classic cytotoxic chemotherapy alone (with/without radiotherapy). To date,
novel molecularly targeted agents have yet to demonstrate benefit in this setting. In the following comprehensive
review we will address the intricacies of perioperative treatment of locally advanced GEC, with focus on clinical trials
supporting the diverse set of perioperative multidisciplinary approaches.
Keywords: Gastric adenocarcinoma, Stomach cancer, Esophageal adenocarcinoma, Esophagogastric (gastroesophageal)
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Gastroesophageal adenocarcinoma (GEC) is a complex
disease which can be broadly classified into proximal
esophagogastric junction (EGJ) and distal gastric cancer
(GC) [1]. At present, surgery is the sole curative option
for operable GEC. Endoscopic mucosal resection (EMR)
is also a possible local therapy for well-differentiated,
non-depressed tumors that are less than 2 cm in size
and invading only up to superficial muscularis (T1a) [2].
EMR for T1aN0 disease is associated with 5-year survival
comparable to surgery and has relatively low mortality* Correspondence: dcatenac@medicine.bsd.uchicago.edu
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distribution, and reproduction in any mediumand morbidity [3]. EMR alone is currently still controver-
sial for T1b (sm1), with reports of 1-3% LN involvement,
while sm2 and sm3 have 10-30% LN involvement [3].
Additionally, EMR can be curative for poorly differenti-
ated intramucosal lesions less than 1 cm, and in non-
poorly differentiated or non-ulcerated tumors less than
2 cm in size [4].
For more advanced disease, the type of surgical approach
and extent of surgery depends upon the anatomical loca-
tion, extent, and TNM stage of the tumor, and is beyond
the scope of this review [3]. For the most part, there is con-
sensus regarding surgical approach for Siewert type I (con-
sidered esophageal cancers), treated by either an en bloc
transthoracic or transhiatal esophagectomy with two-fieldd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.jhoonline.org/content/6/1/66lymphadenectomy. For type III EGJ tumors (gastric cardia),
a total gastrectomy via laparotomy and D2 lymphade-
nectomy without routine distal splenopancreatectomy is
recommended. For Siewert type II EGJ tumors, either of
these procedures are accepted approaches [3,5]. Although
there is some controversy, proximal stomach tumors
(including gastric cardia) require either a total gastrec-
tomy or proximal gastrectomy with resection of 5 to
10 cm of esophagus. Tumors of the middle third/fundus
of the stomach usually require a total gastrectomy, how-
ever tumors of the distal third of the stomach can undergo
radical subtotal (75-85%) gastrectomy [6]. Most trials have
demonstrated that achieving a R0 resection is critical
and is prognostic of improved 5-year survival for both EGJ
and GC, in contrast to R1/R2 resection (microscopic/
macroscopic tumor) [7].
With respect to D1 versus D2 dissection, a recent
metaanalysis evaluating 5 RCTs, involving 1642 patients
with GC enrolled from 1982 to 2005, revealed a higher
operative mortality associated with D2 dissections in the
earlier trials, while recent trials have similar rates of
mortality between D2 and D1 lymphadenectomy [8]. AFigure 1 Completed and ongoing perioperative gastroesophageal ad
tumor location. See text and tables for trial references. Abbreviations: SCC
adenocarcinoma. Bolded: clinical trials with results reported; Not Bolded: cltrend of improved survival existed among D2 patients
who did not undergo resection of the spleen or pancreas,
as well as for patients with T3/T4 cancers. Given that D2
resections may improve the accuracy of locoregional sta-
ging and may improve survival when avoiding routine
distal pancreatectomy and splenectomy, most agree that
this modified D2 approach is appropriate and has been
accepted as standard of care in the recent NCCN guide-
lines [9]. The D1 versus D2 variable plays a significant role
when comparing results across various trials (reported and
ongoing) that will be discussed below.
The complexity and heterogeneity of GEC, in terms of
patient ethnicity [10], as well as anatomical, histological,
and molecular subsets, has resulted in a number of cate-
gorizations, perioperative treatment strategies, and surgical
approaches [1,11]. Specifically, the anatomical distinction
of ‘proximal’ (EGJ) versus ‘distal’ (GC) cancer has led to
diverse inclusion/exclusion criteria for clinical trial en-
rollment, embodying various combinations of chemother-
apy and radiation before and/or after surgery (Figure 1).
Supporting evidence of each of these approaches conse-
quently has led to a number of different practices byenocarcinoma clinical trials, demonstrating enrollment criteria by
, squamous cell carcinoma; EGJ, esophagogastric junction; AC,
inical trials that are ongoing.
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varying experience and preference, and discussed in further
detail below.
Modalities of perioperative treatment
Surgery is the required modality of curative intent treat-
ment of locally advanced GEC. Occult peritoneal disease as
the sole site of dissemination reportedly occurs in approxi-
mately 20-25% of GEC patients, according to several large
retrospective analyses [1]. Perioperative debulking, hyper-
thermic intraperitoneal chemotherapy (HIPEC), and other
novel immunological approaches have been evaluated as
part of the curative intent strategy, mostly in Asia, recently
reviewed elsewhere [1]. A number of clinical trials have
established various perioperative treatment options that
further improve mOS compared to surgery alone, includ-
ing i) neoadjuvant chemoradiation (CRT→S), ii) adjuvant
CRT (S→CRT), iii) neoadjuvant chemotherapy (C→S),
iv) adjuvant chemotherapy (S→C), v) perioperative chemo-
therapy (sandwich approach) (C→S→C), and vi) in-
duction chemotherapy followed by neoadjuvant CRT
(C→CRT→S). The following is a summary of phase III
trials supporting each of these strategies (Table 1; Figure 1).
Comparisons to surgery alone
i. Neoadjuvant chemoradiotherapy (CRT→S) vs.
surgery alone
Before 2010, there were four main trials in this category
where a majority of patients enrolled had AC histology
compared to SCC. All of these trials used cisplatin and
5-flourouracil along with radiation therapy (RT) [12-14]
except the trial by Urba et al. which used cisplatin, 5-
fluorouracil and vinblastine along with RT [15]. The
doses of RT ranged from 35 Gy [13] to 50.4 Gy [14]. In
these trials, the majority of tumors were AC and located
in the mid or distal thirds of the esophagus. Only two of
the four trials showed a statistically significant survival
advantage [12,14]; however, both of these trials are faced
with criticism. The trial by Walsh et al. is widely criti-
cized because of an unexpectedly low 3-year survival
rate of 6% in the surgery alone arm versus 32% with
trimodality therapy [12], compared to the 16-30% seen
in the control arms of the other three trials, thus over-
estimating the clinical benefit of trimodality therapy.
Both the trials of Walsh et al. and Tepper et al. were
under accrued with small numbers of patients (total en-
rollment of 113 and 56, respectively) [12,14]. All four
trials showed improvement in pathological complete
response (pCR), but with wide variability, ranging from
12-40%. Given that these four trials were under-accrued,
had conflicting outcomes, and were ‘contaminated’ with
SCC tumors (despite having a majority AC), the
relevance of the four randomized control trials for EGJ
AC remained unclear and controversial. However, ametaanalysis that included these four trials along with 6
other neoadjuvant CRT trials, enrolling exclusively SCC
patients, showed an overall benefit for all-cause mortal-
ity with HR 0.81 (95% CI 0.70-0.93, p = 0.002), and
thus these data were used to support the use of
neoadjuvant CRT for EGJ AC tumors [16]. An updated
meta-analysis was recently reported, with HR 0.78 (95%
CI 0.7-.088; p < 0.0001) [17].
However, most recently the large 363 patient CROSS
trial was reported, which ultimately enrolled EC (SCC) and
EGJ (AC) in a 1:3 ratio, evaluating CRT→S (carboplatin/
paclitaxel/ 41.4Gy) versus S alone [18]. This was the first
large adequately accrued ‘stand-alone’ phase III trial to sup-
port neoadjuvant CRT over surgery alone in this patient
population. There was a pCR of 29% (49% for SCC, 23%
for AC) and R0 resection rate of 92% versus 69% - for
those patients actually receiving surgical resection (i.e. not
intention-to-treat ITT). The overall mOS was 49.4 versus
24 months and HR was 0.67 (95% CI 0.45-0.87, p = 0.02).
However, the subgroup analysis by histology was HR 0.422
(N = 88; 95% CI 0.24-0.79, p = 0.007) for SCC, and HR
0.741 (N = 275; 95% CI 0.53-1.02, p = 0.07) for AC. Despite
these obvious clinically significant differences in outcome
between histological subgroups, there was reportedly not a
significant statistical interaction by histology. Based on
these data, neoadjuvant CRT remains an accepted treat-
ment option for EGJ AC tumors (Type I/II Siewert), par-
ticularly now with carboplatin/paclitaxel chemotherapy
based on ‘CROSS’, and in particular in North America and
the Netherlands. Awaited are the data detailing the dif-
ferences in R0 resection rate, recurrence rates (local vs.
distant), and 1, 3, 5 year survival rates between AC and
SCC tumors between the two treatment groups. It is antici-
pated that the AC group will have derived less benefit from
CRT, in terms of mOS, due to more distant recurrences as
compared to SCC, despite improved local control.
ii. Adjuvant chemoradiotherapy (S→C-CRT-C) vs.
surgery alone
The landmark Macdonald/INT0116 trial randomized
patients to receive adjuvant CRT (one cycle of bolus
5-FU monotherapy, followed by 2 cycles of 5-FU with
concurrent RT (45Gy) for ~5 weeks, followed by 2 more
cycles of 5-FU monotherapy) versus no adjuvant therapy
in 556 patients with stage IB-IV (no distant metastasis,
AJCC 6th edition) GC (80%) or EGJ (20% type III Siewert)
adenocarcinoma [19]. The regimen, referred to herein as
the ‘MacDonald Regimen’, consisted of 5-FU and leu-
covorin administered before and after radiation. Chemo-
therapy (5-FU, bolus 425 mg/m2 per day, and leucovorin,
20 mg/m2 per day, for 5 days) was initiated on day 1 and
was followed by CRT beginning 28 days after the start of
the initial cycle of chemotherapy. CRT consisted of 45 Gy
of radiation at 180 cGy per day, five days per week for
Table 1 Phase III* clinical trials evaluating perioperative therapy for gastroesophageal adenocarcinoma
Study Inclusion Treatment and number
of patients
AC/SCC (%) ITT R0 pCR (%) DR (%) LR (%) Location (%) 3-year OS (%)
AJCC 6th Ed. EGJ Seiwert GC
T/N I II III
i. Neoadjuvant CRT versus surgery alone
Walsh et al. [12], 1996 Locally advanced RT:
40 Gy
A: CRT (PF)→ S: 58 100 NR A: 25 NR NR Esophagus (16 middle 1/3rd;
51 lower 1/3rd; 34 cardia)
0 A: 32
Irish Trial B: S: 55 B: 0 B: 6
p = 0.01
Burmeister et al. [13],
2005
T1-3, N0-1 A: CRT (PF)→ S: 128 62/37 A: 80 A: 12 A: 45 A: 11 Esophagus (21, upper and
middle 1/3; 79 distal 1/3)
0 A: 32
RT: 35 Gy B: S: 128 B: 59 B: 0 B: 41 B: 14 B: 29
p = 0.83
Tepper et al. [14], 2008 T1-3, Nx A: CRT (PF)→ S: 30 75/25 NR A: 40 A: 27 A: 3 Thoracic esophagus & EGJ 0 A: 39 (5-year)
CALGB 9781 RT: 50.4 Gy B: S: 26 B: 0 B: 38 B: 11 B: 16
p < 0.002
Urba et al. [15], 2001 Locally advanced A: CRT (PFV)→ S: 50 NR A: 28 A: 65 A: 19 0 A: 30
RT: 45 Gy B: S: 50 75/25 B: 0 B: 60 B: 42 Esophagus (8 upper 1/3rd;
92 mid and distal 1/3rd)
B: 16
p = 0.15
van Hagen et al. [18],
2012
T1N1 or T2-T3N0-1 A: CRT (TP)→ S: 175 75/25 92 vs. 69 A: 29 A: NR A: NR 49 26 0 0 A: 58
‘CROSS’ Trial Ib-IIIb B: S: 188 AC: 23% B: NR B: NR B: 44
RT: 41.4 Gy B: 0 HR 0.65 (0.49-0.87)
p = 0.003
Subgroup analysis for
AC only: HR 0.74
(0.53-1.02)
p = 0.07
ii. Adjuvant CRT versus surgery alone
Macdonald et al. [19],
2001
T1 – 4 N +
Ib – IV
A: S:→ CRT 281 100/0 NA NA A: 33 A: 19 0 0 20 80 A: 50
Intergroup 0116 RT: 45 Gy C(5FU) – CRT(5FU) –
C(5FU)
B: 18 B: 29 B: 41





















Table 1 Phase III* clinical trials evaluating perioperative therapy for gastroesophageal adenocarcinoma (Continued)
iii. Neoadjuvant chemotherapy versus surgery alone
MRC OEO-2 [27], 2002 Resectable cancer A: C (CF) → S: 400 66/31 A: 60 NR A: 12 A: 8 64 10 0 A: 43 (2 year)
B: S: 402 B: 54 B: 10 B: 8 (26 SCC) B: 34
HR 0.78 (0.67-0.93)
p = 0.004
Schuhmacher et al. [28],
2010
T3 – T4, N0 – N +
(Locally Advanced)
A: C (CF) → S: 72 100/0 A: 84 A: 7 NR NR 53 47 A: 72.7 (2 year)
EORTC 40954 B: S: 72 B: 72 B: 0 B: 69.9
p = 0.46
iv. Adjuvant chemotherapy versus surgery alone
Sakuramoto et al. [31],
2007
T1 – 4 N +
II (excluding T1) – IIIB
A: S → C (S1) 529 100/0 NA NA A: 21.4 A: 2.8 0 0 0 100 A: 80
ACTS-GS Trial B: S: 530 B: 27.1 B: 1.3 B: 70
HR 0.68 (0.5-0.87)
p = 0.003
Bang et al. [34], 2012 T – 4 N + or II-IIIB A: S → C (CapeOx): 520 100/0 NA NA A: 18 A: 4 0 0 2.5 97.5 A: 74 (3-year DFS)
‘CLASSIC’ Trial B: S: 515 B: 26 B: 8 B: 59
HR 0.56 (0.44-0.72)
p < 0.0001
v. Perioperative chemotherapy versus surgery alone
Kelsen et al. [36,37], 1998,
2007
I-III A: C (CF) → S → CF 233 51/44 A: 62 A: 2.5 A: 49 A: 19 51 0 A: 26
RTOG 8911 Any N + B: S: 234 B: 59 B: 0 B: 51 B: 21 B: 23
p = 0.53
Cunningham et al. [38],
2006
T1-4 N + or II-IV A: C (ECF)→ S→ C (ECF):
250
100/0 A: 69 4 A: 24 A: 14 14 12 74 A: 36 (5-year)
‘MAGIC Trial’ B: S: 253 B: 66 B: 37 B: 21 B: 23
HR 0.75 (0.6-0.9)
p = 0.009
Ychou et al. [39], 2011 T1-4 N + or II-IV A: C (CF) → S → C (CF):
113
100/0 A: 84 3 A: 30 A: 24 11 64 25 A: 38 (5-year)
FFCD9703 Trial B: 38 B: 26 B: 24





















Table 1 Phase III* clinical trials evaluating perioperative therapy for gastroesophageal adenocarcinoma (Continued)
vi. Comparison of post-operative chemotherapy regimens
Bajetta et al. [43], 2012 N + or N0 with T2b-4 A: S → C (CPT-11 +
5-FU/LV – TXT + CDDP):
562




B: S → C (5-FU/LV): 538 HR: 1.00 (0.83-1.20);
p = 0.98
Kobayashi Yoshida et al.
[44], 2012
T3-4, N0-2 A: S → C (UFT): 359 100/0 NA NR NR NR None 100 No significant
difference in DFS
between C + D and
A + B
‘SAMIT’ Trial B: S → C (S1): 364 HR: 0.92 (0.80-1.07);
p = 0.273
C: S→ C (T – >UFT): 355
D: S → C (T – > S1): 355
vii. Adjuvant CRT comparing peri-RT chemotherapy regimens
Fuchs et al. [46], 2011 Locally Advanced A: S → C (5FU/LV)→
CRT (5FU)→ C (5FU/LV):
280
100/0 NR NR NR NR None 100 A: 50
CALGB 80101 B: S → C (ECF)→ CRT
(5FU)→ C (ECF): 266
B: 52
NCT00052910 HR 1.03 (0.80-1.34)
p = 0.80
viii. PET directed therapy
Lordick et al. [50], 2007 cT3/4 Locally
advanced
C (CF)→ Assess for
metabolic response
100/0 NA A: 58 NR NR 68 32 0 0 A: Not reached
Phase II Municon trial A: Response→ C→ S: 54 B: 0 B: 25.8 (2.3 years
median follow up)
B: No-Response→ S: 56 (Major Histologic
Response)
HR = 2.13 (1.14-3.99)
P = 0.015




C (CF)→ Assess for
metabolic response
100/0 NA A: 36 A: 30 A: 9 69 31 0 0 A: 71


























Table 1 Phase III* clinical trials evaluating perioperative therapy for gastroesophageal adenocarcinoma (Continued)
ix. Induction chemotherapy followed by CRT versus chemotherapy or CRT alone
Stahl et al. [57], 2009, T3/4, Nx A: C (PLF)→ CRT (PE) →
S: 60
100/0 A: 72 A: 16 A: 23 NR 54 46 0 A: 47.4
‘POET’ Trial B: C (PLF)→ S: 59 B: 70 B: 2 B: 41 B: 27.7
HR 0.67 (0.41-1.07)
p = 0.07
Alberts et al. [58], 2013 T3-4, N0 or Tany, N(+) A: C (DOX) → CRT
(5Fu + Ox): 21
100/0 NA A: 33 NR NR 40 0 NR
N0849 Trial B: CRT alone: 21 B: 48 (SCC 55)
P = 0.53
x. Adjuvant chemotherapy versus CRT
Lee et al. [26], 2012 II-IV A: S → C (XP): 228 100/0 NA NA A: 25 A: 8.3 0 0 5 95 A: 74.2 (3-year DFS)
‘ARTIST’ Trial Any N+ B: S → C (XP) →
CRT (X)→ C (XP): 230
B: 20 B: 4.8 B: 78.2
p = 0.35 p = 0.086
* unless otherwise indicated.
Abbreviations: AC adenocarcinoma; SCC squamous cell carcinoma; ITT intention to treat; pCR pathological complete response; DR distant recurrence; LR local recurrence; EGJ esophagogastric junction; GC distal gastric
cancer; OS overall survival; RT radiation therapy; CRT chemoradiotherapy; PF cisplatin and 5-flourouracil; NR not reported; PFV cisplatin, 5-flourouracil and vinblastine; TP carboplatin and paclitaxel; 5FU/L 5-flouroacil and
leucovorin; NA not applicable; HR hazard ratio; C chemotherapy alone; CF cisplatin and 5-flourouracil; CapeOx capecitabine and oxaliplatin; XP capecitabine and cisplatin; ECF epirubicin, cisplatin and 5-flourouracil;
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http://www.jhoonline.org/content/6/1/66five weeks, with bolus 5-FU (400 mg/m2 per day) and
leucovorin (20 mg/m2 per day) on the first four and the
last three days of radiotherapy. One month after the com-
pletion of radiotherapy, two five-day cycles of 5-FU (bolus
425 mg/m2 per day) plus leucovorin (20 mg/m2 per day)
were given one month apart. The treatment completion
rate was 64%. The trial showed improvement in mOS of
36 versus 27 months (HR 0.76, CI 0.62-0.92, p = 0.005),
3 year DFS (50 vs. 41%), and local recurrence rate (19 vs.
29%) with this adjuvant strategy. These data were recently
updated and revealed a similar and persistent benefit, en-
suring that adjuvant CRT with 5-FU remains a standard of
care [20,21]. Of note, only 46% of the patients enrolled
underwent ≥D1 surgical resection (only 10% D2) [19]. A
subset analysis showed benefit in all subgroups except
diffuse-type histology [20,22]. Caveats of this trial include
the small number (l0%) of patients undergoing D2 resec-
tion (and even D1 only 36%); it has been argued that
the benefit gained by the addition of CRT merely offset
the inadequate surgical approach (i.e. cleaning up a ‘bad
surgery’). However, a retrospective analysis by Kim et al.
compared 544 patients all receiving D2 resection fol-
lowed by CRT for GC, to 446 receiving D2 surgery alone at
their institution [23]. They reported that both mOS (95.3
vs. 62.6 months, p = 0.02) and mDFS (75.6 vs. 52.7 months,
p = 0.0160) were significantly improved in the S→CRT
group compared to surgery alone. A follow-up small phase
III trial (N = 90) of stage III/IV (TNM-6) patients suggested
that the addition of radiation therapy to chemotherapy
could improve the locoregional recurrence-free survival
(LRRFS) but not disease-free survival of gastric cancer
treated with R0 gastrectomy and D2 lymph node dissec-
tion; a subgroup analysis of only stage III disease did sig-
nificantly prolong the 5-year LRRFS and disease free
survival rates compared with chemotherapy (93.2% vs
66.8%, p = 0.014; 73.5% vs 54.6%, p = 0.056, respectively)
[24]. In contrast, another study reported no difference
in survival in their single institution observational cohort
(N = 142); a subgroup analysis of patients with LN +
disease and higher N-ratio trended to improved clinical
outcomes [25]. The negative ARTIST trial, discussed
below, sought to prospectively evaluate the benefit of adju-
vant CRT compared to adjuvant chemotherapy alone, in
patients having a D2 lymphadenectomy, and also suggested
benefit only within the LN + subgroup [26].
iii. Neoadjuvant chemotherapy (C→S) vs. surgery alone
There are two main randomized controlled trials in this
group (that include AC) [27,28], of which only one trial
was statistically significant [27]. Both trials included SCC
and both used preoperative chemotherapy with cisplatin
(Cis) and 5-fluorouracil (5-FU) - but with different dos-
ing regimens and schedules: 2 cycles Cis-80 mg/m2, 5FU
1000 mg/m2 days 1–4 administered every three weeks[27]; or Cis-50 mg/m2 D 1, 15, 29 and 5FU 2000 mg/m2
D1, 8, 15, 22, 29, 36 [28] - each followed by surgery and
compared to surgery alone. The only positive trial was
the OEO2 trial by the Medical Research Council (MRC)
group, which randomized 871 patients (434 vs. 437), and
enrolled ~64% of patients with EGJ AC (10% type III,
56% type I/II), the remainder being SCC of the esophagus.
The HR for mOS was 0.78 (95% CI 0.67-0.93) and showed
a statistically significant 2-year survival advantage with 43%
versus 34% survival in favor of chemotherapy (P = 0.004)
[27], without reported interaction by histology. The recent
long-term update of OEO2 confirmed the survival benefit
with preoperative chemotherapy with HR 0.84 (p = 0.03)
and 5-year rate of 23% vs. 17.1% [29]. However, the
EORTC 40954 trial, which planned to enroll 360 patients
in order to detect a HR of 0.71 with 80% power and 2-
sided significance level of 4%, ultimately closed early due
to poor accrual with only 40% of the intended patients
(72 per arm). As might be expected, the HR for mOS and
mPFS were not statistically different at 0.84 (p = 0.466)
and 0.76 (p = 0.2), respectively [28].
Differences in treatment dosing, ‘contamination’ with
SCC histology, under accrual (EORTC 40954) and con-
flicting results of these two trials leave an approach
of neoadjuvant 5FU/Cisplatin chemotherapy alone without
definitive evidence to refute or support its use. The meta-
analyses discussed above, which included both neoadjuvant
CRT→S and C→S trials, revealed survival benefit to
chemotherapy alone [16,17]. In the first meta-analysis, the
hazard ratio for neoadjuvant chemotherapy was 0.90
(0.81–1.00; p = 0.05), with a 2-year absolute survival benefit
of 7%. There was no significant effect on all-cause mortal-
ity of chemotherapy for patients with SCC (HR 0.88 [0.75–
1.03]; p = 0.12), although there was a significant benefit for
those with adenocarcinoma (0.78 [0.64–0.95]; p = 0.014)
[16]. The updated meta-analysis showed a HR for all-
cause mortality for all neoadjuvant chemotherapy pa-
tients (AC and SCC) of 0.87 [0.79-0.96; p = 0.005] [17].
The MRC OEO5 study is ongoing and evaluating two
variables - a more aggressive triple drug regimen adding
epirubicin (ECX) and for longer duration (4 cycles), ver-
sus CF (2 cycles) as in the OEO2 - results of which are
awaited [30] (Table 2).
iv. Adjuvant chemotherapy (S→C) vs. surgery alone
In the ACTS-GS trial from Japan, 1059 GC patients
(50% Stage II, 40% Stage III AJCC 6th edition), who all
underwent D2 dissection, were randomized to either ob-
servation or S-1 chemotherapy (40 mg/m2 BID x 4 weeks,
2 weeks off ) for 1 year [31,32]. Of note, 97% of patients
had a T2 or T3 lesion and 90% of patients had N1 or N2
disease. There was a significant improvement in mOS
with S-1 chemotherapy compared to observation that
was maintained in the 5-year update with HR 0.67 (95% CI
Table 2 Ongoing phase II and III trials in locally advanced gastroesophageal adenocarcinoma
Trial Setting N (To be enrolled) Location Primary endpoint Intervention Expected completion date
Alderson et al. [30], 2013 Neoadjuvant 842 Esophageal Survival and QOL A: C (ECX x 4)→ S NR
MRC OEO5 EGJ I-II B: C (CFx2)→ S
Kang et al. [35], 2013 Adjuvant CRT 1000 Gastric and EGJ DFS (3 years) A: S→ C (S1) January 2016
NCT01761461 B: S → C (S1x1)→ CRT (S1)→ C (S1x6)
‘ARTIST II’ C: S → C (SOX)
D: S→ C (SOX)→ CRT (S1)→ C (SOXx4)
Lorenzen et al. [53], 2010 Neoadjuvant CRT NR Resectable EGJ (I-II) Non-randomized, single institution Not initiated
NCT01271322 A: C (Cisplatin/Taxotere) → PET
‘HICON’ Trial (Phase II) If Response: Continue C
If No response: Cross to Arm B
B: Taxane based CRT (45 Gy)→ PET
If Response: CRT (TP x 3)
If No response: Cross to Arm A
Goodman et al. [54], 2013 Neoadjuvant CRT 204 Esophageal and EGJ I and II pCR A: C (FOLFOX x 3)→ PET September 2011
NCT01333033 If Response: CRT (FOLFOX x 3)
CALGB 80803 (Phase II) If No response: Cross to Arm B
B: C (TP x 3)→ PET
If Response: CRT (TP x 3)
If No response: Cross to Arm A
Nordwest et al. [74], 2012 Perioperative 590 Gastric EGJ I-III DFS (2 years) A: C (FLOTx4)→ S (D2)→ C (FLOTx4) July 2015
NCT01216644 B: C (ECFx3) → S (D2)→ C (ECFx3)
‘FLOT4’
Chen et al. [72], 2012 Perioperative 722 Gastric EGJ II or III DFS (3 years) A: C (SOX)→ S (D2)→ C (SOX) September 2014
NCT01583361 B: S (D2)→ C (SOX)
‘RESONANCE’
Shen et al. [73], 2012 Perioperative 1059 Gastric EGJ I-III DFS (3 years) A: S (D2)→ C (SOXx8) September 2014
NCT01534546 B: S (D2)→ C (XELOXx8)
C: C (SOXx3)→ S (D2)→ C (SOXx5)
→ C (S-1x3)
Reynolds et al. [60], 2013 Perioperative 366 Esophageal EGJ (I-III) OS (3 years) A: C (ECF)→ S → C (ECF) September 2021
NCT01726452 B: CRT (TP)→ S
‘MAGIC vs. CROSS EGJ’
Verheji et al. [61], 2011 Perioperative CRT 788 Gastric OS A: C (ECCx3)→ S (D1+)→ CRT (CC, 45Gy) June 2013




















Table 2 Ongoing phase II and III trials in locally advanced gastroesophageal adenocarcinoma (Continued)
Leong et al. [62], 2013 Peri-operative CRT 752 Gastric EGJ OS A: C (ECF/Xx2)→ CRT (5-FU/RT)→ S
→ C (ECF/Xx3)
NR
‘TOP GEAR’ (Australia) B: C (ECF/Xx3) → S→ C (ECF/Xx3)
Molecularly targeted trials
Safran et al. [67], 2013 Neoadjuvant CRT 480 Mid and Distal Esophagus
including EGJ
DFS A: CRT (TP) → S → T (13) August 2018
NCT01196390 B: CRT (TP)→ S
RTOG 1010




Ilson et al. [69], 2012 Neoadjuvant CRT 420 Esophageal (Squamous allowed)
GEJ I-II
OS A: CRT (CCT, 50.4 Gy) August 2018
NCT00655876 B: CRT (CT, 50.4 Gy) -Closed at interim analysis
for AC arm due to low
clinical complete response
RTOG 0436 -Closed SCC arm due to
SCOPE-1 results (see text)
Cunningham et al. [75],
2012
Perioperative 1100 Gastric EGJ I-III OS, Safety, Efficacy A: C (ECXB)→ S → C (ECXB) December 2014
NCT00450203
‘MAGIC-B’ (ST03) B: C (ECX)→ S → C (ECX)
Abbreviations: PET positron emission tomography; FLOT 5-flourouracil, leucovorin, oxaliplatin and docetaxel; FOLFOX 5-FU, leucovorin and oxaliplatin; XELOX oxaliplatin with capecitabine; ECC epirubicin, cisplatin, capecitabine;
CDP cisplatin, docetaxel, panitumumab; CCT cetuximab, cisplatin, and paclitaxel; SOX S-1 and oxaliplatin; TP paclitaxel and carboplatin; T trastuzumab; B bevacizumab; QOL Quality of Life; 5-FU/L 5-flouroacil and leucovorin;
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authors concluded that S-1 is an effective adjuvant treat-
ment after D2 dissection in East Asian patients with locally
advanced GC [31,32].
Paoletti et al. conducted a large metaanalysis of 17
RCTs with individual patient data for 3838 patients to
evaluate the efficacy of adjuvant chemotherapy (het-
erogeneous regimens) compared to surgery alone. They
reported an absolute 5- year overall survival advantage of
5.7% with adjuvant chemotherapy compared to surgery
alone (55.3 vs. 49.6% respectively, HR 0.82, CI 0.76-0.90,
P = 0.001) with similar HR for DFS [33].
Recently, the ‘CLASSIC’ trial was reported by Bang et al.
in stage II-IIIB GC patients [34]. All patients underwent
curative D2 gastrectomy and were enrolled from 37 centres
in South Korea, China, and Taiwan. Patients were random-
ized to either observation or adjuvant chemotherapy with
8 cycles of CapeOx (oral capecitabine, 1000 mg/m2 BID on
D 1–14 of each 3 week cycle, plus oxaliplatin 130 mg/m2
on D1 of each 3 week cycle) for 6 months. The trial showed
significant improvement in the 3-yr OS (83% vs. 78%, HR
0.72, 95% CI 0.62-1; p = 0.0493) and 3-yr DFS with adjuvant
CapeOx compared to surgery alone (74 vs. 59%, HR 0.56,
95% CI 0.44-0.72; p < 0 · 0001); mature data for robust esti-
mates of mOS are awaited. The adjuvant chemotherapy
was associated with more grade ≥ 3 toxicity compared to
surgery alone (56% vs. 6% respectively) with nausea, neutro-
penia, and decreased appetite as the major toxicities [34].
The four arm ‘ARTIST-II’ trial, assesses S1 monotherapy
versus S1 and oxaliplatin (SOX) with or without CRT (with
concurrent S1) in LN + disease only [35] (Table 2).
v. Perioperative ‘sandwich’ chemotherapy (C→S→C) vs.
surgery alone
The trial, INT-0113/RTOG8911, by Kelsen et al. random-
ized 467 patients (53% AC) to surgery alone or to 3
monthly preoperative cycles and 2 post-operative cycles of
Cisplatin 100 mg/m2 and 5FU 1000 mg/m2 days 1–5
[36,37]. This resulted in no difference in survival (p = 0.53)
[36], yet updated results revealed that patients who
responded to chemotherapy radiographically (n = 39, 19%
total, 12% PR, 7% CR) had a substantial improvement
in long term survival, while the non-responders did not
differ significantly from those undergoing surgery alone,
a phenomenon that was similar to the MUNICON
studies discussed below. Moreover, R0 resection proved
to be a major determinant of long-term survival, and the
chemotherapy (ITT) group had a R0 rate of 63% versus
59% (ITT) [36,37]. Of note, in multivariate analysis,
for patients assigned to chemotherapy and surgery, not
responding to chemotherapy (HR, 2.83; 95% CI, 1.84 to
4.35; p<0.0001) and >10% weight loss (HR, 1.47; 95% CI,
1.09 to 1.98; p =0 .0109) were associated with increased
risk of death, while adenocarcinoma histology (HR, 0.59;95% CI, 0.44 to 0.80) was associated with decreased risk of
death. Only 70% of patients received all three cycles of pre-
operative therapy, and only 30% of patients received at
least one post-operative cycle [36,37].
In contrast, two large randomized controlled trials,
‘MAGIC’ and the FNLCC ACCORD07-FFCD9703 trial,
established the role of perioperative chemotherapy in im-
proving survival compared to surgery alone [38,39]. Both
of these trials included only patients with AC histology,
with ~25% and 75% EGJ tumors in ‘MAGIC’ and FFCD
trials, respectively.
The ‘MAGIC’ trial enrolled 503 patients randomizing to
3 cycles of ECF before and 3 cycles after surgery, compared
to surgery alone. This resulted in an improvement in mOS
with HR 0.75 (95% CI 0.60-0.93, p = 0.009) and 5-yr sur-
vival rate of 36% versus 23% compared to surgery alone.
There was a similar benefit in PFS with HR 0.66 (95% CI
0.53-0.81, p < 0.001). Only 66% of the patients started post-
operative chemotherapy and 76% of these patients actually
completed the planned course of chemotherapy; only 41.6%
of patients completed all 6 cycles of therapy. This is a sig-
nificantly higher completion rate than in the INT-0113 trial,
discussed above [36,37]. There was a significant trend to
having fewer patients in the advanced T-stage (p = 0.002)
and N + groups (p = 0.01) within the perioperative chemo-
therapy group, despite randomization. Only 41% of patients
received a D2 resection, (D1 19%, D0 40%). R0 resection
was observed in 79% versus 69% of patients in favor of the
chemotherapy arm (ie. not ITT). It should be noted that
91.6% of patients in the C→S→C arm underwent surgery,
while 96.4% underwent surgery in the control arm. More
patients did not proceed to surgery in the chemotherapy
arm (6.1%) versus the surgery alone arm (2.4%), many of
which progressed during the neoadjuvant chemotherapy
phase, thus excluding them from curative-intent surgery. It
can be argued that this neoadjuvant approach delaying im-
mediate resection actually spared this subset of patients
with aggressive disease from unnecessary surgery, which
would have unlikely changed the ultimate outcome.
The ACCORD07 trial randomized patients to cisplatin
(100 mg/m2) and 5FU (800 mg/m2 D1-5) every 28 days
(N = 113) for up to 3 cycles prior to surgery and up to
4 cycles after surgery, versus surgery alone (N = 111) (D2
recommended) [39]. The trial slightly underaccrued from
its target enrollment of 250 patients. Most patients in the
chemotherapy arm received 2 cycles preoperatively (78%),
and 87% of patients received at least 2 preoperative cycles.
Among those who received at least 1 cycle of preoperative
chemotherapy (n = 109), 54 patients (50%) received at least
1 cycle of post-operative therapy (6/7/16/25 patients re-
ceived 1/2/3/4 cycles postoperatively, respectively). Of
those who relapsed (55% vs. 64%), locoregional only relapse
was low (12 vs. 8% in the chemotherapy vs. surgery alone,
respectively), compared to the aggregate of distant relapse
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for surgery alone). This emphasized the systemic nature of
GEC. The mOS was improved with HR 0.69 (95% CI 0.50-
0.95, p = 0.02) with 5-yr survival rates of 38% vs. 24%. DFS
similarly was improved with HR 0.65 (95% CI 0.48-0.89,
p = 0.003) with 5-yr DFS rates of 34% vs. 19%. R0 resec-
tion rate was observed in 84% vs. 74% of patients. The
subgroup analysis of EGJ patients (comprising 75% of
accrued patients) for mOS, revealed a HR 0.57 (95% CI
0.39-0.83). Caveats to both the ‘MAGIC’ and ‘ACCORD-
07’ trials were lack of pre-treatement staging as endo-
scopic ultrasound was as yet unavailable. Given very
similar results between ‘MAGIC’ and ‘ACCORD-07’, the
additional benefit of epirubicin in this setting has been
questioned, which may be potentially addressed in the on-
going OEO5 trial (without a post-operative chemotherapy
component), discussed above.
Interestingly, phase II reports with FLOT and DCF ‘sand-
wich’ chemotherapy have reported pCR rates of 10-12%, and
R0 rates ranging ~85-100%, supporting the ongoing evalu-
ation of these regimens in larger trials [40-42] (Table 2).
With similar survival benefits as measured by HR and
absolute 5-year survival rates of the ‘sandwich’ approach
to neoadjuvant CRT for EGJ AC, perioperative treatment
with ECF or CF are accepted standards, particularly in
Britain, Europe and some centers in North America.
vi. Comparison of post-operative chemotherapy regimens
S→FOLFIRI then DC vs S→5FU
The ITACA-S trial evaluated whether intensification of
postoperative chemotherapy would improve outcomes of
patients undergoing curative intent resection of GC or EGJ
AC. Patients with ≥D1-lymphadenectomy were random-
ized to irinotecan 180 mg/m2 on d1, LV 100 mg/m2 d1-2,
5-FU 400–600 mg/m2 d1-2, q14; (FOLFIRI regimen) for
4 cycles, followed by docetaxel 75 mg/m2 d1, cisplatin
75 mg/m2 d1, q 21; (DC regimen) for 3 cycles (arm A) as
compared to the ‘control’ arm of LV 100 mg/m2 d1-2,
5-FU 400–600 mg/m2 d1-2, q 14 for 9 cycles (arm B).
Patients were randomized (562 arm A, 538 arm B) by 123
Italian centers. The primary endpoint of DFS was not sta-
tistically different between the groups (HR 0.98; 95% CI
0.83-1.16; p = 0.83), nor was there an observed difference
in mOS (HR 1.00; 95% CI 0.83-1.20; p = 0.98). The authors
concluded that adjuvant chemotherapy for GC/EGJ with a
more intensive regimen did not result in a significant pro-
longation of DFS and OS when compared to the bolus/
infusion FU/LV regimen, suggesting that intensification of
chemotherapy may not improve outcomes [43].
(S→UFT vs S→S1 vs S→paclitaxel then UFT vs.
S→ paclitaxel then S1)
The four arm SAMIT trial was a phase III trial with a
two-by-two factorial design planned to assess the survivalbenefit of adjuvant chemotherapy intensificaiton via se-
quential use of paclitaxel and oral flurinated pyrimides
(FP) in comparison to FP alone, and to compare the
FPs tegafur/uracil (UFT) versus S-1. An initial report
showed that adjuvant chemotherapy with various combina-
tions of taxol and fluoropyrimindines was well tolerated
[44]. Recently, the final results were reported, where the
primary endpoint of DFS revealed that UFT was inferior to
S-1 (HR 1.23, 1.07-1.43), and that there was a nonsignifi-
cant trend (HR 0.92, 0.8-1.07; p = 0.23) to improved DFS
with sequential PTX→FP versus FP alone [45].
These two trials, SAMIT and ITACA-S, suggest that
intensification of chemotherapy does not improve survival
over fluoropyrimidine alone.
vii. Adjuvant CRT comparing peri-RT chemotherapy
regimens
(S→5FU-CRT-5FU vs S→ ECF-CRT-ECF)
The CALGB 80101 trial by Fuchs et al. compared post-
operative CRT with intensified peri-RT chemotherapy
using ECF versus the standard 5FU treatment [46]. How-
ever, the control arm received a modified ‘Macdonald
regimen’, with continuous infusion (CI) 5FU 200 mg/m2
everyday through to completion of radiation (45Gy), rather
than the original bolus 5FU concurrently with RT. The in-
vestigational arm received 1 cycle of ECF chemotherapy
before and 2 cycles ECF after CRT, in 546 patients with
GC or EGJ AC (~33%). The trial did not show any signifi-
cant difference between the ECF and 5-FU arms for mOS
(HR, 1.03; 95% CI, 0.80-1.34; p = 0.8) or 3-yr DFS (52 vs.
50% respectively). Counter-intuitively, the toxicity com-
parison between the 5-FU arm compared to the ECF arm
revealed a slightly higher treatment related mortality (3%
vs. <1% respectively) as well as grade 4 toxicity (40% vs.
26% respectively, p < 0.001); this may be attributed to the
different peri-RT chemotherapy dose schedules of the 5FU
between the arms (bolus ‘Macdonald regimen’ versus con-
tinuous infusion). The authors concluded that there is no
survival advantage of postoperative CRT using intensified
peri-RT ECF compared to 5-FU [46]. The authors also in-
dicated that there was an approximate 40% D2 resection
rate, but that accurate D0/D1/D2 resection rates will be
reported at a later date [46].
viii. PET directed therapy
Sarkaria et al. conducted a retrospective study using a
prospectively maintained database to determine if endo-
scopic biopsy after neoadjuvant CRT therapy would predict
pathological CR (pCR) [47]. It was observed that a negative
endoscopic biopsy was not reliable for predicting pCR,
nodal stage or overall survival. Overall, PET imaging for
predicting pathologic response in EGJ has been most
promising. In a retrospective study, Weber and colleagues
first established that a SUV decrease of ≥35% from baseline
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and specificity of 95% [48]. The SUV cut-off was subse-
quently validated prospectively by Ott et al. [49]. They also
found that metabolic responders showed a high histopath-
ologic response rate of 44% compared to only 5% in meta-
bolic non-responders (p = 0.001) [49]. This led to a single
center, exploratory, phase II ‘MUNICON’ study in patients
with EGJ cancer [50]. Enrolled patients (N = 119 EGJ I/II)
were originally staged as cT3 or cT4 based on CT, EUS,
and PET. A repeat PET scan at day day 14 into treatment,
as compared to baseline, was done to assess the metabolic
response to chemotherapy (cisplatin and 5-FU). Res-
ponders continued with chemotherapy for 12 weeks,
while non-responders proceeded directly to surgery. In
metabolic non-responders, mOS was 25.8 months (19.4–
32.2), whereas mOS was not reached in responders after a
follow-up of 2.3 years (HR 2.13, CI 1.14–3.99, p = 0.015). A
major histological remission (<10% residual tumor) was
found in 58% of metabolic responders, compared to none
in metabolic non-responders. R0 resection rates were 82%
in PET-responders, and 70% in non-responders. Import-
antly, a comparison of these observed results to historic co-
horts showed that discontinuing inactive chemotherapy
after 2 weeks, and avoiding delay in surgery, did not ad-
versely affect outcomes [51]. Based on these results, the
‘EUROCON’ trial planned to randomize metabolic nonre-
sponders after 2 weeks of chemotherapy to immediate re-
section or CRT followed by surgery, but this trial did not
materialize. However, the smaller ‘MUNICON-II’ trial was
completed (N = 56, EGJ I/II) where PET-responders were
continued on chemotherapy alone (cisplatin 50 mg/m2 days
1, 15, and 29; 5FU 2000 mg/m2 over 24 hours days 1, 8,
15, 22, 29, repeated on day 49; folinic acid 500 mg/m2
over 2 hours with each 5FU administration), while non-
responders proceeded with neoadjuvant CRT prior to
surgery [52]. This design had the power to detect an im-
provement in the R0 resection rate from 74% to 94% in
non-responders (1-sided alpha 0.1, power 0.8), with re-
quirement of treating 23 non-responders with salvage
neoadjuvant CRT (32 Gy with 1.6 Gy twice daily and 10
fractions per week; cisplatin 6 mg/m2 days 1–5 and 8–12
OR 5FU 250 mg/m2 CI if renal function inadequate). Of
the 56 patients enrolled, 23 were non-responders and
obtained ‘salvage’ CRT prior to surgery. The 2-year sur-
vival rates were 74% vs 57% (p = 0.035) in favor of the
PET-responders. Although there was an increased histo-
pathological response observed in the ‘MUNICON-II’
salvage CRT non-responder group (as compared to the
‘MUNICON I’ trial histopathological rate, where non-
responders proceeded directly to surgery without further
neoadjuvant treatment), the primary endpoint was not
reached in ‘MUNICON-II’ with an observed R0 resec-
tion rate of 74%, not significantly better than the R0
rate of 70% observed in ‘MUNICON-I’. ‘MUNICON-II’confirmed the poor prognosis of PET non-responders
(which is approximately 50-60% of EGJ I/II patients),
despite aggressive salvage neoadjuvant CRT. The authors
concluded that despite salvage neoadjuvant CRT in PET-
nonresponders leading to local remissions in 6 (16%) of
patients, it was not able to change the clinical course in
general because of the systemic disease recurrence pat-
terns. They also surmised that improvement of distant re-
currence would be required to improve outcomes for this
patient subset. Criticism of the MUNICON-II trial is the
relatively low dose of radiation, as well as the single agent
Cisplatin (or 5FU) during CRT, which is less aggressive
than desired for optimal local control.
In addition to the ‘MUNICON-I and -II” trials, the
‘HICON’ and CALGB 80803 clinical trials plan to evalu-
ate PET-directed treatment in the neoadjuvant setting
prior to surgery for EGJ, as discussed below [53-55]. Un-
fortunately, the HICON trial was never initiated. More-
over, PET directed therapy is being evaluated for locally
advanced GC where patients with baseline PET tumor
SUV > 3.5 (or tumor : liver ratio > 1.5) receive one cycle
(C1) epirubicin (50 mg/m2), cisplatin (60 mg/m2) day and
capecitabine (625 mg/m2 twice daily days 1–21) (ECX)
with bevacizumab (15 mg/kg day 1) therapy preoperatively
for 21 days, with a repeat post-C1 PET. Patients with a
metabolic response (>35% decrease in FDG uptake) on re-
peat PET proceed with two further cycles of the initial
treatment. PET nonresponders switch to ‘salvage’ docetaxel
(30 mg/m2) and irinotecan (50 mg/m2) Days 1 and 8 every
3 weeks, along with bevacizumab (15 mg/kg day 1), for
two cycles. Postoperatively, patients continue on the
chemotherapy regimen they received just prior to surgery
for three more cycles [56]. Twenty of 60 planned patients
were enrolled before closure of this trial to poor accrual;
11/20 had PET response. Ten of 11 (91%) responders
achieved R0 resection and 4/11 (36%) achieved patho-
logical responses (1 pCR, 3 pPR). Seven of 9 (77%) PET
non-responders achieved R0 resection; none achieved a
pathological response. There was no significant differ-
ence in DFS between the responders and non-responders
(p = 0.4). This hypothesis generating pilot trial demon-
strated that PET imaging during induction chemotherapy
can identify early treatment failures, with potential bene-
fit of altering to salvage chemotherapy. This has led to
the proposal of a larger Cooperative Group trial currently
under consideration.
ix. Induction chemotherapy followed by chemoradiation
(C→CRT→S vs. C→S; C→CRT→S vs. CRT→S)
One reported trial, ‘POET’, assessed the benefit of induc-
tion chemotherapy followed by concomitant CRT in ran-
domized fashion versus chemotherapy alone, (unlike
‘MUNICON-II’, discussed above, where only PET-non-
responders of ‘induction’ chemotherapy proceeded with
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with PLF (cisplatin, leucovorin and 5-fluorouracil), com-
prised of cisplatin 50 mg/m2 biweekly and weekly 5FU
2000 mg/m2 with leucovorin (one course 6 weeks) [57].
The investigational arm completed 2 courses of PLF
followed by RT with concurrent PE (cisplatin 50 mg/m2 D
1,8 and etoposide 80 mg/m2/day D 3–5) compared to the
‘control arm’ of chemotherapy alone using PLF for 2.5
courses (15 weeks) followed by surgery. This trial, then,
was comparing neoadjuvant chemotherapy with/without
CRT prior to surgery. Unique inclusion criteria included
only high-risk T3-4 patients with EGJ AC (Siewert’s I-III).
The trial required pre-operative staging with EUS and
laparoscopy. Unfortunately, the accrual goal was not met
(only 33% of the planned patients were recruited, N = 119).
The trial showed a trend towards improvement in 3 year
OS with induction chemotherapy followed by CRT (47 vs.
28%, respectively) but it was not statistically significant
(HR 0.67, CI 0.41-1.07, p = 0.07). Additionally, the pCR
rates (16 vs. 2%) and local control (77 vs. 59%) were better
in the investigational CRT arm compared to the chemo-
therapy alone control [57]. The comparison of induction
chemotherapy prior to CRT versus chemotherapy alone
seemed promising in this trial, albeit using an unconven-
tional chemotherapy of etoposide during RT. However,
from the ‘MUNICON-II’ trial (with recognized caveats of
potentially underdosed RT and inadequate concurrent
chemotherapy with cisplatin alone), it appeared that non-
responders to chemotherapy alone did not derive large
therapeutic benefit from further neoadjuvant CRT in terms
of survival or R0 resection rates, while chemotherapy re-
sponders had improved outcomes. Therefore, it is possible
that chemotherapy responders may be treated optimally
with chemotherapy alone, without deriving benefit from
additional CRT. To prospectively study this, a trial exclu-
sively evaluating chemotherapy responders randomized to
continued chemotherapy versus intensified CRT could be
done, in order to determine if CRT adds anything to those
already responding to chemotherapy alone. Similarly, to
evaluate the utility of induction chemotherapy prior to
CRT (assuming the need for CRT), a prospective random-
ized trial of induction chemotherapy prior to CRT versus
CRT alone would be required. One such trial, N0849, was
recently reported, with the primary endpoint assessing
pCR rate [58]. The interim report on efficacy and fu-
tility revealed a pCR rate of 7/21 (33%) in the induc-
tion chemotherapy arm versus 10/21 (48%) in the CRT
alone arm, and R0 resection rates of 16/17 (94%) ver-
sus 20/20 (100%), respectively. The authors concluded
the induction chemotherapy failed to improve pCR rates,
yet followup in regard to survival and rate (and site) of re-
currence is ongoing [58]. One might suggest that addition
of induction chemotherapy would not be expected to im-
prove pCR rates, but rather and if anything, decreasedistant recurrence rates - data which are currently
not mature. Regardless, the principle of C→CRT prior to
surgery for all patients, whether there is response or not to
the induction chemotherapy, is being evaluated in CALGB
80803 trial using a PET directed algorithm with chemo-
therapy backbone cross-over if there is demonstrated lack
of PET response - intentions of optimizing both local (RT)
and distant (chemotherapy) control [54] (Table 2).
x. Adjuvant chemotherapy versus CRT
(S→C vs. S→C-CRT-C)
In addition to the small trial by Kim et al. above [24],
Lee et al. treated 458 resected GC patients with post-
operative chemotherapy in the ‘ARTIST’ trial, with 2 cycles
of XP (capecitabine and cisplatin), followed by concurrent
capecitabine with RT, followed by 2 more cycles of XP,
compared to post-operative chemotherapy consisting of
6 cycles of XP alone [26]. Again, all patients underwent D2
gastrectomy and had R0 resection of GC (only 5% type III
EGJ). The primary endpoint of the trial, DFS, was not met
with 3-yr DFS rates available at the time of reporting
(78.2% vs. 74.2%; P = 0.0862). However, a subgroup analysis
of LN + disease (N = 396, 86%) did reveal improved DFS
with HR 0.6865 (95% CI 0.47-0.99; P = 0.047) [26]. The
authors, due to the nature of subgroup analyses, caution
regarding conclusions with respect to LN + disease, and in-
dicate that a subsequent trial, ‘ARTIST-II’, will prospectively
evaluate the utility of C→CRT→C versus chemotherapy
alone (S1 versus S1 and oxaliplatin - SOX) in LN + disease
undergoing D2 resection in a four-arm trial [35]. The
‘ARTIST-II’ trial will evaluate the question of intensification
in LN + only disease. The results from ‘ARTIST’ suggest
that low-stage (N-) disease may be adequately treated with
modified D2 resection without the need for CRT.
The devil is in the details: which perioperative
approach?
Adding the recent trials ‘CROSS’, CALGB 80101,
‘CLASSIC’, ‘ITACA-S’, ACCORD07 and ‘ARTIST’ to the
repertoire of pre-2010 studies evaluating various periopera-
tive treatment strategies, no regimen has emerged with
international consensus for GC or EGJ AC cancers. Ex-
cluding the ‘ITACA-S’, SAMIT, ‘ARTIST’, CALGB80101,
and ‘POET’ trials, all of the discussed relevant stand-alone
phase III trials compare the investigational arm to surgery
alone, making direct comparison of differing perioperative
approaches complicated. We are limited to cross-trial com-
parisons and meta-analyses, and the caveats and shortcom-
ings that this entails, including differences in enrollment
criteria and actual enrollment variances, such as tumor lo-
cation (i.e. GC/EGJ mix) (Figure 1). For instance, EGJ AC
tumors are less-well represented within S→CRT and S→C
trials, whereas they do comprise a more substantial subset
within C→S→C, C→CRT→S, and CRT→S trials.
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stage (eg. most enrolled ≥ stage II, but some enrolled ≥
stage Ib; whether EUS and/or staging laparoscopy/wash-
ings were performed), and other nuances such as propor-
tion of D1/D2 surgery, chemotherapy and radiotherapy
type, dose and/or schedule, and geographic location/ethnic
makeup variances from trial to trial, all make cross-trial
comparisons quite problematic.
While there is consensus that ‘something-other-than-
surgery-alone’ should be done for GEC, and in particular
EGJ AC, with consistent clinical improvement observed
regardless of the perioperative approach chosen (~10-15%
absolute 5-yr survival benefit, HR 0.60-0.80), opinions re-
garding C→S→C vs CRT→S differ, and are formulated
based on cross-trial comparisons and clinician experiences.
For patients seeking second/third opinions, this can be par-
ticularly confusing when they receive different opinions re-
garding treatment strategy. The ‘CROSS’ authors favor
CRT→S for EGJ AC, stating that the ‘ACCORD-07’ and
‘MAGIC’ trials have a heterogeneous distribution of GC
and EGJ patients, as well as citing the under-accrued rela-
tively small ‘POET’ trial as supporting arguments [18].
However, the ‘POET’ trial was not a comparison of
C→S→C to CRT→S, but rather C→S to C→CRT→S, and
had unique T-stage eligibility (Table 1), used non-standard
CRT with etoposide, under-accrued, and ultimately, had a
non-significant survival difference. Moreover, ‘ACCORD-
07’ accrued 75% EGJ patients, and subset survival analysis
of these EGJ patients showed a HR 0.57 (0.39 to 0.83), al-
beit without statistically significant interaction by tumor lo-
cation, possibly due to lack of power of this analysis.
Furthermore, the ‘CROSS’ trial also had significant differ-
ences in eligibility, namely, histology (SCC 25%); despite
the statement that benefit was consistent across histologic
subgroups without interaction, the AC patients clearly
demonstrated less benefit in terms of pCR, recurrence, and
survival (HR 0.74 (0.53-1.02)). Finally, as demonstrated by
the relapse patterns of the ‘ACCORD07’ and ‘MUNICON’
trials, distant recurrence is the apparent challenge for EGJ
AC, for all patients, whether treated with chemotherapy,
CRT or surgery alone, underscoring the systemic nature of
EGJ AC. Until superior approaches are available that
diminish distant recurrence, local control will be less
important in terms of survival benefit, in contrast to the
SCC histology. An important exception includes the sce-
nario when R0 resection is deemed unattainable without
RT prior to surgery. Again, although the pCR rate with
neoadjuvant chemotherapy alone is low, ranging from 2-
7% [36,38,39,57], these lower pCR rates, as compared to
CRT (20-25%), appear to be less important than R0 re-
sections in predicting long-term survival. With chemo-
therapy alone, absolute R0 rates are improved over
surgery alone approximately 10% (eg. ACCORD 07: 74%
to 84%, MAGIC 69% to 79%). Despite these rates beinglower than those of CRT→S in some trials (CROSS 68
to 90% for AC) compared to surgery alone, the HR and
absolute 5-year survival rates are similar between the two
strategies. In contrast, R0 resections rates were not
significantly different in the POET trial comparing
C→S to C→CRT→S (70 vs 72%, respectively; Table 1)
[57]. However, if RT is determined to be required to
optimize R0 resection at multi-disciplinary tumor
board, such as with T4 tumors, then it is appropriate to
proceed accordingly [59]. Therefore, in general, higher
pCR and even R0 resections seen with neoadjuvant CRT
do not correlate with long-term overall survival improve-
ment in comparison to ‘sandwich’ chemotherapy strat-
egies (with the limitations of cross-trial comparisons).
This is likely a function of the systemic propensity of
GEC and ultimate distant recurrence. Moreover, as
discussed above in PET-directed therapy, the MUNICON
II trial may provide an explanation for the apparent lack
of significant survival differences between the CRT→S
and C→S→C strategies. It is plausible that any of the
survival benefits observed in the various CRT→S trials
could be attained with chemotherapy alone (either C→S
or C→S→C). This is akin to the chemotherapy-
responders in MUNICON II. On the other hand, for
chemotherapy-nonresponders, it doesn’t matter what one
does, the survival outcome is unchanged (hence no need
for RT at all, in either scenario). Prospective evaluation of
these questions are warranted to assess these pertin-
ent questions. Finally, more aggressive chemotherapy with
FLOT and DCF ‘sandwich’ regimens have reported higher
pCR rates of 10-12% and R0 rates of ranging 85-100%
than previous ECF or CF regimens, which merit further
testing in several ongoing trials (Table 2) [40-42].
Cross-trial comparisons to determine best treatment
approach must be done understanding key differences in
eligibility criteria of the trials in question – particularly
primary tumor location (Figure 1), stage, and histology –
as well as surgical technique, pre-treatment staging and
nuances of chemoradiotherapy type, dose, and schedule.
The Devil is in the details.
Evidence that there is lack of consensus for optimal
perioperative treatment of GEC, and in particular EGJ, is
reflected by a number of current ongoing trials (Table 2).
Fortunately, some of these trials are directly compar-
ing the various perioperative strategies head-to-head.
These include ‘RESONANCE’ and ‘SOX’, trials which
are evaluating the ‘sandwich’ chemotherapy approach
(with various chemotherapy backbones) compared to
post-operative chemotherapy alone. The ‘ARTIST II’, as
discussed above, seeks to confirm, prospectively, the per-
ceived post-operative CRT benefit within the ‘ARTIST’
LN + subgroup in patients undergoing R0 D2 resection,
as well as the intensification of chemotherapy question
(SOX vs S-1) in this population in a 4-arm trial [35].
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definitively demonstrate superiority of CRT to chemother-
apy alone, with the acknowledged numerous caveats of
such comparisons (HR 0.88 (0.76-1.01; p = 0.07)) [17]. Sup-
porters of CRT point to trends in survival benefit, whereas
supporters of chemotherapy alone argue that there are no
definitive data to support significant superiority (statisti-
cally or clinically) of CRT over chemotherapy alone. To an-
swer the question of whether C→S→C or CRT→S is best
for EGJ, the planned 366 patient ‘MAGIC vs. CROSS
Upper GI’ trial randomizes patients with AC of the EGJ
(I/II/III) to the standard ‘MAGIC’ or ‘CROSS’ regimen
[60]. Finally, the addition of RT to the perioperative
‘sandwich’ approach is being evaluated in direct compari-
son to the standard ‘sandwich’ approach in the ‘CRITICS’
(RT post-operative, >D1 surgery, GC and Type III EGJ,
N = 788) [61] and ‘TOP GEAR’ (RT pre-operative, D2 or
D1+ for EGJ requiring an esophago-gastrectomy, GC and
Type II/III EGJ excluding tumors that involve >2 cm distal
esophagus, N = 752) [62]. Results of each of these pivotal
large randomized phase III trials will be eagerly awaited
and will optimistically clarify a number of uncertainties
faced currently in this arena. Of course, it is likely that new
questions will arise from these studies, and very possibleTable 3 Medium-throughput targeted sequencingТ of GEC pa
demonstrating profound interpatient molecular heterogeneit
Patient Oncogene
1 HER2 Amp+, SRC Amp+, TOP1 Amp+
2 FGFR2 Amp+
3 SRC Amp+, AURKA Amp+, CCND1 Amp+, CDK4 Amp
RICTOR Amp+, MDM2 Amp+





9 HER2 Amp+, PIK3CA mt
10
11 CCND1 Amp+, EZH2 mt, FGF19 Amp+, FGF3 Amp+, FGF4
12
13 PIK3CA mt, ERBB3 mt, AXL mt, KDR mt
14






21 HER2 mt, ERBB3 mt
Legend: Amp+: Amplified, mt: mutation.
Т Sequencing performed using Foundation One Platform (first generation – 186 gen
platform (236 genes).that results may not establish a consensus approach for the
perioperative treatment of GEC, if outcomes are similar
between comparator groups. Should this be the case (that
CRT versus chemotherapy are not substantially different in
outcome), other factors such as patient quality of life (ie.
requiring daily treatment for ~5 weeks versus chemother-
apy every 2–3 weeks, toxicity differences, etc.) and/or treat-
ment regimen cost will likely play a role in establishing
treatment standards.
Addition of molecularly targeted agents
to perioperative therapy
The integration of ‘molecularly targeted’ agents to peri-
operative GEC therapy is complicated, again, by the
various available ‘backbone’ strategies reviewed above.
Addition of novel agents to neoadjuvant CRTare underway
with anti-EGFR (cetuximab, SCOPE 1 and RTOG0436;
panitumumab, ACASOGZ4051), anti-HER2 for HER2+
tumors (trastuzumab, RTOG1010), and anti-angiogenesis
(bevacizumab) [63-69]. The RTOG0436 trial, evaluat-
ing ~350 patients with EGJ and EC (AC and SCC) with
paclitaxel, cisplatin, RT with/without cetuximab, revealed
only a modest endoscopic CR rate which triggered an early
stopping rule in AC histology; the trial was then open fortients undergoing curative intent resection
y
Tumor suppressor
TP53 mt, CDH1 mt
+, CDKN2A/B Loss, ATM mt
TP53 mt, PTEN mt
TP53 mt, FANCA Loss
ARID1A mt, ARID2 mt, Smad2 mt, MLL2 mt
TP53 mt
CDH1 mt, CDH1 Splice Site mt
Amp+
CDH1 Splice Site mt, CDKN2A mt, ARID1A mt, ARID2 mt
NF1 mt, ARID1A mt, CREBBP mt, CTCF mt, MLH1 mt
ARID1A mt
TP53 mt, FBXW7 mt, PTEN mt
TP53 mt, CDKN2A mt
CDH1 Splice Site mt, LRP1B mt, MLL2 mt
TP53 mt, KDM6A splice mt
TP53 mt
TP53 mt (x2), DNMT3A mt, MSH2 mt
es), except patients 11–21, who were sequenced on the second generation
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served treatment-related fatalities and inferiority to stand-
ard treatment with the addition of cetuximab to CRT
in the SCOPE 1 (C→CRT +/− cetuximab →S; 73% SCC
esophagus, 27% EGJ AC) trial [63], and served as the
basis to fully close all arms of RTOG0436. This observa-
tion of potential intolerable toxicity and/or survival detri-
ment with the addition of novel molecularly targeted
agents to RT in this setting may hinder further develop-
ment along these lines [70,71].
On the other hand, introducing novel agents to chemo-
therapy alone may have less toxicity, and therefore it may
be more conducive to evaluate these agents along with
perioperative approaches that do not incorporate RT,
particularly given the above arguments that there has not
been definitive evidence to suggest superiority of CRT
based regimens versus non-CRT regimens. A number
of studies (MRC OEO5, NCT01761461, NCT01534546,
NCT01583361, and FLOT4) [30,35,72-74] are underway
(Table 2), evaluating for optimal ‘backbone’ chemother-
apy regimens and sequence. Trials, including ST03, (aka
‘MAGIC 2’, ECX+/−bevacizumab) [75], seek to address the
question of benefit of targeted agents added to chemother-
apy backbones. There is also continued evaluation of the
PET directed strategies discussed above [49-53,55].
Due to several negative trials in the metastatic setting,
the SCOPE-1 results, and the lack of significant clinical
CR rate for AC observed in RTOG0436, further evalu-
ation of anti-EGFR therapy is unlikely to be pursued in
the perioperative setting, at least in unselected patients.
Additionally, there is suggestion that there may be a
negative interaction, or at best no improvement, of adju-
vant C→CRT→C in HER2+ patients within the INT-
0116 trial, albeit with very small numbers [76]. Along
with RTOG 1010 evaluating trastuzumab in neoadjuvant
CRT approach, it is anticipated that anti-HER2 therapies
will be evaluated in HER2+ EGJ/GC patients using the
‘sandwich’ chemotherapy backbone. However, difficulties
in accrual to perioperative clinical trials are exacerbated
by the low frequencies of molecular ‘oncogenic drivers’;
this is the case for HER2+ disease, comprising only 10-20%
of GEC. Potentially ‘actionable’ oncogenic drivers including
MET, KRAS, PIK3CA, FGFR2, SRC and others have even
less frequent genomic activation in GEC (Table 3). There-
fore, there is great need for novel clinical trial designs and
strategies using medium throughput technologies and
treatment algorithms with access to multiple therapeutic
agents within the same trial, in order to address this in-
creasingly recognized challenge [77].
Conclusions
GEC is one of the most common malignancies and sec-
ond highest cause of cancer mortality worldwide. The ex-
tensive heterogeneity of etiology, patient ethnicity, tumorlocation, histology, and trial inclusion/exclusion criteria,
have resulted in diverging treatment algorithms with lack
of consensus worldwide. Trials are in motion in order to
directly address these controversies, yet results will not
be available for several years (ie ‘MAGIC vs CROSS Upper
GI’ final data are expected ~2021). Ultimate treatment
plans should be derived by multi-disciplinary review. Re-
gardless, all current standard perioperative approaches im-
prove absolute 5-yr survival for GEC patients ~10-15%,
leaving much room for improvement. The promise of
‘personalized’ cancer care with therapies targeted toward
specific molecular aberrations has great potential to sig-
nificantly improve clinical outcomes. However, there is
emerging understanding of the immense molecular het-
erogeneity within GEC (inter-patient heterogeneity), and
even within an individual (intra-patient heterogeneity)
(Table 3) [77]. This heterogeneity is a hurdle to advancing
GEC treatment via targeted therapies. Current clinical trial
design paradigms are challenged by heterogeneity, as they
are unable to test targeted therapeutics against low fre-
quency genomic aberrations with adequate power. Collab-
orative group multicenter and international studies with
innovative designs and novel molecular diagnostic tech-
nologies will be necessary in order to accomplish these dif-
ficult but attainable goals [77,78].
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